COVID-19: Vaccines and Therapeutics
McKesson Corporation will serve as a central distributor of future COVID-19 vaccines and related supplies, the departments of Health and Human Services and Defense announced.
The departments of Health and Human Services and Defense will pay Moderna Inc. about $1.5 billion to produce and deliver 100 million doses of its COVID-19 vaccine candidate to vaccinate Americans if authorized by the Food and Drug Administration, the agencies announced.
The departments of Health and Human Services and Defense will pay Janssen Pharmaceutical Companies of Johnson…
The Department of Health and Human Services announced that it will partner with the Department of Defense to fund the advanced development — including clinical trials and large-scale manufacturing — of a COVID-19 investigational vaccine from Sanofi and GlaxoSmithKline.
The Department of Health and Human Services’ Biomedical Advanced Research and Development Authority issued a $265 million task order reserving vaccine manufacturing capacity through December 2021 at an advanced manufacturing center in Texas.
Atrium Health President and CEO Eugene Woods spoke on CBS’s Face the Nation about the lack of reagents for COVID-19 testing, racial disparities during the pandemic and treating thousands of COVID-19 patients in their homes.
The National Institutes of Health announced that a COVID-19 vaccine candidate co-developed by Moderna, Inc. and the National Institute of Allergy and Infectious Diseases has begun a phase 3 clinical trial.
The National Academies of Sciences, Engineering, and Medicine and the National Academy of Medicine July 24 will host its inaugural committee meeting on the equitable allocation of a COVID-19 vaccine.
The Department of Health and Humans Services said it has an agreement with Pfizer to produce and deliver 100 million doses of the drug maker’s COVID-19 vaccine candidate.
A COVID-19 trial vaccine developed by the University of Oxford and AstraZeneca produced neutralizing antibody responses in patients with SARS-CoV-2, according to a study published July 20 in The Lancet.